HK Stock Market Move | HUTCHMED (00013) rose more than 3%, the results of the SACHI III study were published in The Lancet.

HUTCHMED(00013) rose more than 3%, by the time of publication, it rose by 2.9% to 24.1 Hong Kong dollars, with a trading volume of 57.287 million Hong Kong dollars. In terms of news, according to HUTCHMED's official WeChat account, on January 14, HUTCHMED announced that the results of the SACHI III study were published in "The Lancet". SACHI is a Phase III study of the combination therapy of savolitinib (savolitinib) and osimertinib (Tagrisso) for the treatment of EGFR mutation positive locally advanced or metastatic non-small cell lung cancer patients who have disease progression after receiving first-line EGFR tyrosine kinase inhibitor (TKI) treatment with MET amplification. Savolitinib is a potent, highly selective oral MET TKI developed jointly by AstraZeneca and HUTCHMED, and commercialized by AstraZeneca. Osimertinib is an irreversible third-generation EGFR TKI. Based on the data from the SACHI study, the combination therapy of savolitinib and osimertinib was approved in China in June 2025.